Cancer Research and Treatment

Review Article

Cellular Dormancy in Cancer: Mechanisms and Potential Targeting Strategies: Hye-Young Min, Ho-Young Lee; Cancer Res Treat. 2023;55(3):720-736. Published online March 22, 2023; DOI: https://doi.org/10.4143/crt.2023.468

Cancer is a leading cause of disease-related mortality worldwide. Drug resistance is one of the primary reasons for the failure of anticancer therapy. There are a number of underlying mechanisms for anticancer drug resistance including genetic/epigenetic modifications, microenvironmental factors, and tumor heterogeneity. In the present scenario, researchers have focused on these novel mechanisms and strategies to tackle them. Recently, researchers have recognized the ability of cancer to become dormant because of anticancer drug resistance, tumor relapse, and progression. Currently, cancer dormancy is classified into “tumor mass dormancy” and “cellular dormancy.” Tumor mass dormancy represents the equilibrium between cell proliferation and cell death under the control of blood supply and immune responses. Cellular dormancy denotes the state in which cells undergo quiescence and is characterized by autophagy, stress-tolerance signaling, microenvironmental cues, and epigenetic modifications. Cancer dormancy has been regarded as the stem of primary or distal recurrent tumor formation and poor clinical outcomes in cancer patients. Despite the insufficiency of reliable models of cellular dormancy, the mechanisms underlying the regulation of cellular dormancy have been clarified in numerous studies. A better understanding of the biology of cancer dormancy is critical for the development of effective anticancer therapeutic strategies. In this review, we summarize the characteristics and regulatory mechanisms of cellular dormancy, introduce several potential strategies for targeting cellular dormancy, and discuss future perspectives.

Citations

Citations to this article as recorded by

Design, synthesis and antitumor activity of 4-arylamine substituted pyrimidine derivatives as noncovalent EGFR inhibitors overcoming C797S mutation
Yaqing Zuo, Zhiwu Long, Rongrong Li, Yi Le, Silong Zhang, Huan He, Longjia Yan
European Journal of Medicinal Chemistry.2024; 265: 116106. CrossRef
Unveiling the role of cellular dormancy in cancer progression and recurrence
Evelyne Collignon
Current Opinion in Oncology.2024; 36(2): 74. CrossRef
Mitophagy-Mediated Tumor Dormancy Protects Cancer Cells from Chemotherapy
Yunqing Sun, Yang Chen, Zhenan Liu, Jingjing Wang, Junqiang Bai, Ruixue Du, Mingshu Long, Zhengjun Shang
Biomedicines.2024; 12(2): 305. CrossRef
Survival strategies: How tumor hypoxia microenvironment orchestrates angiogenesis
Mengrui Yang, Yufeng Mu, Xiaoyun Yu, Dandan Gao, Wenfeng Zhang, Ye Li, Jingyang Liu, Changgang Sun, Jing Zhuang
Biomedicine & Pharmacotherapy.2024; 176: 116783. CrossRef
Colorectal cancer and dormant metastases: Put to sleep or destroy?
Marina A Senchukova
World Journal of Gastrointestinal Oncology.2024; 16(6): 2304. CrossRef
Tumor Dormancy and Reactivation: The Role of Heat Shock Proteins
Haneef Ahmed Amissah, Stephanie E. Combs, Maxim Shevtsov
Cells.2024; 13(13): 1087. CrossRef
Advancements in Understanding the Hide-and-Seek Strategy of Hibernating Breast Cancer Cells and Their Implications in Oncology from a Broader Perspective: A Comprehensive Overview
Aiman Al-Ruwishan, Bushra Amer, Ahmed Salem, Ahmed Abdi, Namoonga Chimpandu, Abdelmonem Esa, Alexandros Melemenis, Muhammad Zubair Saleem, Roselit Mathew, Yaser Gamallat
Current Issues in Molecular Biology.2024; 46(8): 8340. CrossRef
Prospects of compounds of herbal plants as anticancer agents: a comprehensive review from molecular pathways
Putri Cahaya Situmorang, Syafruddin Ilyas, Sony Eka Nugraha, Rony Abdi Syahputra, Nik Mohd Afizan Nik Abd Rahman
Frontiers in Pharmacology.2024;[Epub] CrossRef
Deciphering genetic and nongenetic factors underlying tumour dormancy: insights from multiomics analysis of two syngeneic MRD models of melanoma and leukemia
Marie-Océane Laguillaumie, Sofia Titah, Aurélie Guillemette, Bernadette Neve, Frederic Leprêtre, Pascaline Ségard, Faruk Azam Shaik, Dominique Collard, Jean-Claude Gerbedoen, Léa Fléchon, Lama Hasan Bou Issa, Audrey Vincent, Martin Figeac, Shéhérazade Seb
Biological Research.2024;[Epub] CrossRef
Deciphering Dormant Cells of Lung Adenocarcinoma: Prognostic Insights from O-glycosylation-Related Tumor Dormancy Genes Using Machine Learning
Chenfei Dong, Yang Liu, Suli Chong, Jiayue Zeng, Ziming Bian, Xiaoming Chen, Sairong Fan
International Journal of Molecular Sciences.2024; 25(17): 9502. CrossRef
Outcomes in ischemic and hemorrhagic stroke patients with cancer: The Japan Stroke Data Bank
Takeshi Yoshimoto, Kazunori Toyoda, Sohei Yoshimura, Shinichi Wada, Masafumi Ihara, Junji Miyazaki, Kaori Miwa, Tomohide Yoshie, Yoshihiro Miyamoto, Shotai Kobayashi, Kazuo Minematsu, Masatoshi Koga
Journal of the Neurological Sciences.2024; 466: 123234. CrossRef
Effect of postsurgical adjuvant chemotherapy timing on outcomes in patients with pancreatic cancer – a systematic review and meta-analysis
Longlan Zhou, Lin Zhang
Journal of Chemotherapy.2024; : 1. CrossRef
Apolipoproteins have a major role in cellular tumor dormancy in triple negative breast cancer: In-silico study
Zaynab El-Gammal, Usama Bakry, Ahmed F. El-Sayed, Toka A. Ahmed, Gehad Atef Oura, Shimaa E. Elshenawy, Nagwa El-Badri, Amin F. Romany, Khaled Amer, Tarek Elnagdy, Osama Mahmoud Azmy, Tarek Taha Ahmed Ali
Scientific Reports.2024;[Epub] CrossRef
Synthesis, In Silico Prediction, and In Vitro Evaluation of Anti-tumor Activities of Novel 4'-Hydroxybiphenyl-4-carboxylic Acid Derivatives as EGFR Allosteric Site Inhibitors
Wurood A. Shihab, Ammar A. Razzak Kubba, Lubna H. Tahtamouni, Khaled M. Saleh, Mai F. AlSakhen, Sana I. Kanaan, Abdulrahman M. Saleh, Salem R. Yasin
Current Medicinal Chemistry.2024; 31(38): 6336. CrossRef
Navigating the Complexity of Resistance in Lung Cancer Therapy: Mechanisms, Organoid Models, and Strategies for Overcoming Treatment Failure
Da Hyun Kang, Jisoo Lee, Subin Im, Chaeuk Chung
Cancers.2024; 16(23): 3996. CrossRef
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S. W. Tan, Suresh S. Ramalingam, Caicun Zhou
Nature Reviews Clinical Oncology.2024;[Epub] CrossRef

6,949 View
381 Download
15 Web of Science
16 Crossref

Special Article

How Can We Treat Cancer Disease Not Cancer Cells?: Kyu-Won Kim, Su-Jae Lee, Woo-Young Kim, Ji Hae Seo, Ho-Young Lee; Cancer Res Treat. 2017;49(1):1-9. Published online December 26, 2016; DOI: https://doi.org/10.4143/crt.2016.606

Abstract PDF PubReader ePub

Since molecular biology studies began, researches in biological science have centered on proteins and genes at molecular level of a single cell. Cancer research has also focused on various functions of proteins and genes that distinguish cancer cells from normal cells. Accordingly, most contemporary anticancer drugs have been developed to target abnormal characteristics of cancer cells. Despite the great advances in the development of anticancer drugs, vast majority of patients with advanced cancer have shown grim prognosis and high rate of relapse. To resolve this problem, we must reevaluate our focuses in current cancer research. Cancer should be considered as a systemic disease because cancer cells undergo a complex interaction with various surrounding cells in cancer tissue and spread to whole body through metastasis under the control of the systemic modulation. Human body relies on the cooperative interaction between various tissues and organs, and each organ performs its specialized function through tissue-specific cell networks. Therefore, investigation of the tumor-specific cell networks can provide novel strategy to overcome the limitation of current cancer research. This review presents the limitations of the current cancer research, emphasizing the necessity of studying tissue-specific cell network which could be a new perspective on treating cancer disease, not cancer cells.

Citations

Citations to this article as recorded by

New Breakthroughs in the Diagnosis of Leptomeningeal Carcinomatosis: A Review of Liquid Biopsies of Cerebrospinal Fluid
Maria Goldberg, Michel G Mondragon-Soto, Ghaith Altawalbeh, Bernhard Meyer, Amir Kaywan Aftahy
Cureus.2024;[Epub] CrossRef
Equine Melanocytic Tumors: A Narrative Review
José Pimenta, Justina Prada, Mário Cotovio
Animals.2023; 13(2): 247. CrossRef
Biology of cancer; from cellular and molecular mechanisms to developmental processes and adaptation
Ion G. Motofei
Seminars in Cancer Biology.2022; 86: 600. CrossRef
Mechanisms of resistance to chemotherapy in non-small cell lung cancer
Hye-Young Min, Ho-Young Lee
Archives of Pharmacal Research.2021; 44(2): 146. CrossRef
The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients
Giovanni Paolino, Veronica Huber, Serena Camerini, Marialuisa Casella, Alberto Macone, Lucia Bertuccini, Francesca Iosi, Elisa Moliterni, Serena Cecchetti, Irene Ruspantini, Flavia Chiarotti, Elisabetta Vergani, Luca Lalli, Carla Raggi, Antonella Di Biase
Cancers.2021; 13(16): 4157. CrossRef
Bone-marrow-derived cell-released extracellular vesicle miR-92a regulates hepatic pre-metastatic niche in lung cancer
Ya-Ling Hsu, Ming-Shyan Huang, Jen-Yu Hung, Wei-An Chang, Ying-Ming Tsai, Yi-Chung Pan, Yi-Shiuan Lin, Hung-Pei Tsai, Po-Lin Kuo
Oncogene.2020; 39(4): 739. CrossRef

18,674 View
336 Download
6 Web of Science
6 Crossref

First
Prev
Page of 1
Next
Last

Search